Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Interleukin-37 protects against acinar cell pyroptosis in acute pancreatitis
Nan Ma, … , Weiqin Li, Jieshou Li
Nan Ma, … , Weiqin Li, Jieshou Li
Published September 27, 2022
Citation Information: JCI Insight. 2022;7(21):e161244. https://doi.org/10.1172/jci.insight.161244.
View: Text | PDF
Research Article Gastroenterology Inflammation

Interleukin-37 protects against acinar cell pyroptosis in acute pancreatitis

  • Text
  • PDF
Abstract

Acute pancreatitis (AP) is a local and/or systemic inflammatory disease that starts with acinar cell injury and necrosis; it has no effective medical treatment and thus remains a life-threatening condition. Interleukin-37 (IL-37), a natural immunomodulator, has demonstrated an antiinflammatory effect; however, the role of IL-37 in AP remains unknown. The serum IL-37 levels of 39 healthy controls and 94 patients with AP were measured. Cholecystokinin was applied to induce pancreatic acinar cell injury in vitro. Classical experimental AP models, such as caerulein, l-arginine, and taurolithocholic acid 3-sulfate disodium salt, were included in the in vivo study. A transgenic mouse model with the IL-37 gene and administration of recombinant IL-37 were used to further investigate the function of IL-37 in AP. Pancreas-specific gasdermin D–knockout (GSDMD-knockout) mice were used to explore the protective mechanism of IL-37. Our results showed that serum IL-37 levels in humans were negatively correlated with the severity of AP. Furthermore, IL-37–transgenic mice and supplementation with recombinant IL-37 could both protect against AP. Mechanistically, IL-37 was able to suppress pyroptosis of injured acinar cells, and specific depletion of GSDMD in the pancreas counteracted the protective effect of IL-37. Our study demonstrates that IL-37 protects against acinar cell pyroptosis in AP.

Authors

Nan Ma, Chenchen Yuan, Juanjuan Shi, Qingtian Zhu, Yang Liu, Xiaojie Ma, Baiqiang Li, Weijuan Gong, Jing Xue, Guotao Lu, Weiqin Li, Jieshou Li

×

Figure 3

Protective effects of IL-37 in TLCS- and ARG-induced AP models.

Options: View larger image (or click on image) Download as PowerPoint
Protective effects of IL-37 in TLCS- and ARG-induced AP models.
(A and B...
(A and B) Taurolithocholic acid 3-sulfate disodium salt (TLCS; 2.5%, 2 mg/kg) was injected in retrograde into the pancreatic bile duct to induce AP in IL37tg and WT mice. The sham group was used as the control in TLCS-induced experimental AP models. (A) H&E staining of pancreatic tissues from the indicated groups at 24 hours, and representative IHC staining of CD68 and MPO in pancreatic tissues. Scale bars: 200 or 50 μm. (B) Percentages of pancreatic cell death area, and serum amylase, lipase, and IL-1β levels at 24 hours (n = 5–6 per group). (C and D) WT and IL37tg littermates were given i.p. injections of 8% l-arginine (ARG; 3.3 g/kg, hourly, 3 times total) to induce AP, while an equivalent volume of PBS was injected into mice from the control group. (C) H&E staining at 72 hours, and representative IHC staining of CD68 and MPO in pancreatic tissues. Scale bars: 200 or 50 μm. (D) Percentages of pancreatic cell death area, and serum amylase, lipase, and IL-1β levels (n = 5–6 per group). Statistical comparisons were made using 1-way ANOVA. Data are presented as mean ± SD, and statistical significance is denoted as **P < 0.01, and ***P < 0.001.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts